What's Happening?
SOPHiA GENETICS has partnered with Synnovis to introduce liquid biopsy testing for lung and breast cancer patients across the U.K. This initiative is part of NHS England's 'blood test-first' program. The test, MSK-ACCESS®, uses SOPHiA DDM™ technology
to analyze circulating tumor DNA (ctDNA) from a single blood draw, offering a minimally invasive alternative to traditional biopsies. The partnership aims to fast-track cancer patients to targeted therapies and reduce the need for invasive treatments. Synnovis is already supporting around 400 patients monthly with this testing, and the program is expected to expand significantly.
Why It's Important?
The introduction of liquid biopsy testing represents a significant advancement in cancer care, offering a less invasive and faster method for detecting genomic alterations. This can lead to earlier and more personalized treatment plans, improving patient outcomes. The partnership between Synnovis and SOPHiA GENETICS highlights the potential of AI-driven precision medicine to transform healthcare delivery. As the demand for such testing grows, it could lead to substantial economic savings for healthcare providers and broaden access to genomic testing for patients who cannot undergo traditional procedures.
What's Next?
The partnership plans to expand the use of liquid biopsy testing to approximately 7,000 patients annually. As adoption increases, this approach could become a model for precision oncology in Europe, potentially influencing healthcare systems worldwide. The collaboration also opens the door for incorporating additional indications into future NHS cancer screening programs, further enhancing the reach and impact of genomic testing services.
